Table 2 Time-to-event anayses of progression and response endpoints.
Indication/endpoint | 1 month (95% CI) | 3 months (95% CI) | 6 months (95% CI) | 12 months (95% CI) | Median time to (95% CI) | Median duration of response (95% CI)a |
|---|---|---|---|---|---|---|
laBCC | ||||||
PFS overall | 100.0 | 90.9 (77.6–96.5) | 74.5 (58.6–85.0) | 44.6 (29.1–58.9) | 10.3 (7.5–22.6) | NA |
PFS STEVIE | 100.0 | 93.3 (61.3–99.0) | 86.7 (56.4–96.5) | 60.0 (31.8–79.7) | 13.6 (6.1–26.6) | NA |
PFS daily practice | 100.0 | 89.7 (71.3–96.5) | 67.8 (47.1–81.8) | 35.4 (17.8–53.6) | 10.2 (5.6–22.6) | NA |
Partial response | 45.5 (32.2–61.2) | 94.6 (84.4–99.0) | NR | NR | 1.1 (0.9–1.8) | 9.7 (6.7–19.9)b |
Complete response | 0.0 | 7.1 (2.3–20.4) | 33.9 (20.6–52.5) | 51.9 (33.2–73.5) | 7.4 (5.8–NE) | 10.3 (4.5–22.1) |
mBCC | ||||||
PFS | 100.0 | 100.0 | 88.9 (43.3–98.4) | 33.3 (7.8–62.3) | 11.7 (5.2–17.5) | NA |
Partial response | 20.0 (5.4–59.1) | 52.0 (25.5–83.9) | NR | NR | 2.5 (0.9–4.2) | 9.2 (3.2–14.5)b |
Complete response | NA | NA | NA | NA | NA | NA |
BCNS | ||||||
PFS | 100.0 | 100.0 | 100.0 | 61.5 (30.8–81.8) | 19.1 (7.4–20.2) | NA |
Partial response | 46.7 (25.6–73.7) | 93.3 (74.0–99.6) | NR | NR | 1.0 (0.9–1.7) | 11.3 (5.0–18.8)b |
Complete response | 0.0 | 7.7 (1.1–43.4) | 40.8 (19.3–72.2) | 88.2 (59.8–99.3) | 6.4 (3.9–11.0) | 8.3 (2.8–16.3) |
